SA517381298B1 - تركيبة صيدلية بثبات محسن - Google Patents
تركيبة صيدلية بثبات محسنInfo
- Publication number
- SA517381298B1 SA517381298B1 SA517381298A SA517381298A SA517381298B1 SA 517381298 B1 SA517381298 B1 SA 517381298B1 SA 517381298 A SA517381298 A SA 517381298A SA 517381298 A SA517381298 A SA 517381298A SA 517381298 B1 SA517381298 B1 SA 517381298B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- lactate
- conjugate
- pharmaceutical composition
- based polymer
- less
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Gynecology & Obstetrics (AREA)
- Biotechnology (AREA)
- Pregnancy & Childbirth (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
يوفر الاختراع الحالي تركيبة قابلة للحقن لتوصيل عقار بإطلاق مقنن وعملية لتكوينها، حيث تشتمل التركيبة على: بوليمر أساسه اللاكتات lactate-based polymer له وزن جزيئي حسب متوسط الوزن يتراوح بين 5000 و50000 دالتونdalton ، عدد حمض أقل من 3 مجم KOH/ جم ومحتوى مونومرات لاكتيد متبقية residual lactide monomers في البوليمر الذي أساسه اللاكتات أقل من نحو 0.3% بالوزن؛ مذيب عضوي مقبول صيدليًا؛ ومادة نشطة حيويًا أو ملح منها تحتوي على سيرين حمض أميني amino acid serine في بنية جزيئية قادرة على التفاعل مع مونومر لاكتيد لتكوين مترافق؛ وحيث تقلل التركيبة تكوين المترافق. [الشكل 25]
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462064008P | 2014-10-15 | 2014-10-15 | |
PCT/US2015/055634 WO2016061296A1 (en) | 2014-10-15 | 2015-10-15 | Pharmaceutical composition with improved stability |
Publications (1)
Publication Number | Publication Date |
---|---|
SA517381298B1 true SA517381298B1 (ar) | 2021-12-18 |
Family
ID=55747307
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SA517381298A SA517381298B1 (ar) | 2014-10-15 | 2017-04-12 | تركيبة صيدلية بثبات محسن |
Country Status (20)
Country | Link |
---|---|
US (2) | US20160106804A1 (ar) |
EP (1) | EP3207149B1 (ar) |
JP (2) | JP6717839B2 (ar) |
KR (2) | KR102274420B1 (ar) |
CN (2) | CN113209009A (ar) |
AU (2) | AU2015332456A1 (ar) |
BR (1) | BR112017007669A2 (ar) |
CA (1) | CA2964475C (ar) |
ES (1) | ES2949827T3 (ar) |
HR (1) | HRP20230716T1 (ar) |
HU (1) | HUE062326T2 (ar) |
IL (1) | IL251703B (ar) |
MX (2) | MX2017005235A (ar) |
NZ (1) | NZ730538A (ar) |
PL (1) | PL3207149T3 (ar) |
RS (1) | RS64339B1 (ar) |
RU (1) | RU2728786C2 (ar) |
SA (1) | SA517381298B1 (ar) |
SG (1) | SG11201702535QA (ar) |
WO (1) | WO2016061296A1 (ar) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160106804A1 (en) * | 2014-10-15 | 2016-04-21 | Yuhua Li | Pharmaceutical composition with improved stability |
JP7125403B2 (ja) * | 2017-01-04 | 2022-08-24 | ファーマシェン エス.エー. | 高分子量の生分解性ポリマーを調製するための方法 |
UA127018C2 (uk) * | 2017-01-31 | 2023-03-15 | Веру Інк. | КОМПОЗИЦІЇ ТА СПОСОБИ ТРИВАЛОГО ВИВІЛЬНЕННЯ АНТАГОНІСТІВ ГОНАДОТРОПІН-ВИВІЛЬНЯЮЧОГО ГОРМОНА (GnRH) |
US20200282008A1 (en) * | 2017-01-31 | 2020-09-10 | Veru Inc. | COMPOSITIONS AND METHODS FOR LONG TERM RELEASE OF GONADOTROPIN-RELEASING HORMONE (GnRH) ANTAGONISTS |
KR102522654B1 (ko) | 2017-12-18 | 2023-04-17 | 포시 파마슈티컬스 컴퍼니 리미티드 | 선택된 방출 기간을 갖는 약제학적 조성물 |
AU2022323754A1 (en) | 2021-08-05 | 2024-02-08 | Medincell S.A. | Pharmaceutical composition |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4443340A (en) | 1981-10-09 | 1984-04-17 | Betz Laboratories, Inc. | Control of iron induced fouling in water systems |
JPS60100516A (ja) * | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
DE3708916A1 (de) | 1987-03-19 | 1988-09-29 | Boehringer Ingelheim Kg | Verfahren zur reinigung resorbierbarer polyester |
US5702716A (en) | 1988-10-03 | 1997-12-30 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
US5487897A (en) | 1989-07-24 | 1996-01-30 | Atrix Laboratories, Inc. | Biodegradable implant precursor |
US5324519A (en) | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
EP0452111B1 (en) | 1990-04-13 | 1998-07-15 | Takeda Chemical Industries, Ltd. | Biodegradable high-molecular polymers, production and use thereof |
USRE37950E1 (en) | 1990-04-24 | 2002-12-31 | Atrix Laboratories | Biogradable in-situ forming implants and methods of producing the same |
AU2605592A (en) | 1991-10-15 | 1993-04-22 | Atrix Laboratories, Inc. | Polymeric compositions useful as controlled release implants |
DE69230032T2 (de) | 1991-12-19 | 2000-02-03 | Mitsui Chemicals Inc | Polyhydroxycarbonsäure und verfahren zu ihrer herstellung |
EP0560014A1 (en) | 1992-03-12 | 1993-09-15 | Atrix Laboratories, Inc. | Biodegradable film dressing and method for its formation |
US5242910A (en) | 1992-10-13 | 1993-09-07 | The Procter & Gamble Company | Sustained release compositions for treating periodontal disease |
US5681873A (en) | 1993-10-14 | 1997-10-28 | Atrix Laboratories, Inc. | Biodegradable polymeric composition |
BR9507313B8 (pt) | 1994-04-08 | 2016-06-07 | Atrix Lab Inc | composição líquida de liberação adequada para a formação de um implante de liberação controlada, sistema polimérico, curativo fílmico microporoso biodegradável, e, precursor de um implante de liberação controlada para a implantação em um indivíduo |
US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
FR2776516B1 (fr) * | 1998-03-25 | 2001-05-25 | Pharma Biotech | Compositions presentant une liberation prolongee et leur procede de preparation |
AR012448A1 (es) * | 1997-04-18 | 2000-10-18 | Ipsen Pharma Biotech | Composicion en forma de microcapsulas o de implantes que comprende un excipiente biodegradable, polimero o co-polimero, o una mezcla de talesexcipientes, y una sustancia activa o una mezcla de sustancias activas, procedimiento para la preparacion de una sustancia soluble en agua de elevada |
US6261583B1 (en) | 1998-07-28 | 2001-07-17 | Atrix Laboratories, Inc. | Moldable solid delivery system |
US6143314A (en) | 1998-10-28 | 2000-11-07 | Atrix Laboratories, Inc. | Controlled release liquid delivery compositions with low initial drug burst |
US6565874B1 (en) | 1998-10-28 | 2003-05-20 | Atrix Laboratories | Polymeric delivery formulations of leuprolide with improved efficacy |
ATE289205T1 (de) | 1998-12-15 | 2005-03-15 | Takeda Pharmaceutical | Verfahren zur herstellung biologisch-abbaubarer polyester |
US6355657B1 (en) | 1998-12-30 | 2002-03-12 | Atrix Laboratories, Inc. | System for percutaneous delivery of opioid analgesics |
US6461631B1 (en) | 1999-11-16 | 2002-10-08 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
US8470359B2 (en) | 2000-11-13 | 2013-06-25 | Qlt Usa, Inc. | Sustained release polymer |
DK1660039T3 (en) * | 2003-07-18 | 2017-01-16 | Oakwood Laboratories L L C | PREVENTION OF REDUCTION OF THE POLYMER MOLECULE WEIGHT, THE PREPARATION OF PURPOSES AND GELING IN POLYMER COMPOSITIONS |
US8313763B2 (en) | 2004-10-04 | 2012-11-20 | Tolmar Therapeutics, Inc. | Sustained delivery formulations of rapamycin compounds |
JP5244394B2 (ja) | 2004-11-10 | 2013-07-24 | トルマー セラピューティクス, インコーポレイテッド. | 安定化されたポリマー送達系 |
KR101728868B1 (ko) * | 2006-01-18 | 2017-05-02 | 포시 파마슈티컬스 컴퍼니 리미티드 | 안정성이 강화된 약학 조성물 |
DK2054073T3 (da) * | 2006-07-11 | 2015-03-02 | Foresee Pharmaceuticals Inc | Farmaceutiske præparater til fremføring med langvarig frigivelse af peptider |
HUE025842T2 (en) * | 2007-02-15 | 2016-04-28 | Tolmar Therapeutics Inc | Poly (lactide / glycolide) with reduced fracture properties and methods for producing polymers |
US9090737B2 (en) * | 2007-11-13 | 2015-07-28 | Surmodics, Inc. | Viscous terpolymers as drug delivery platform |
RU2014150367A (ru) | 2008-08-29 | 2015-06-27 | Джензим Корпорейшн | Лекарственные средства с контролируемым высвобождением, содержащие пептиды |
US20160106804A1 (en) * | 2014-10-15 | 2016-04-21 | Yuhua Li | Pharmaceutical composition with improved stability |
-
2015
- 2015-10-14 US US14/883,183 patent/US20160106804A1/en not_active Abandoned
- 2015-10-15 EP EP15850568.5A patent/EP3207149B1/en active Active
- 2015-10-15 JP JP2017539512A patent/JP6717839B2/ja active Active
- 2015-10-15 MX MX2017005235A patent/MX2017005235A/es unknown
- 2015-10-15 HR HRP20230716TT patent/HRP20230716T1/hr unknown
- 2015-10-15 CN CN202110616661.7A patent/CN113209009A/zh active Pending
- 2015-10-15 RU RU2017111079A patent/RU2728786C2/ru not_active Application Discontinuation
- 2015-10-15 WO PCT/US2015/055634 patent/WO2016061296A1/en active Application Filing
- 2015-10-15 KR KR1020197007340A patent/KR102274420B1/ko active IP Right Grant
- 2015-10-15 NZ NZ730538A patent/NZ730538A/en unknown
- 2015-10-15 SG SG11201702535QA patent/SG11201702535QA/en unknown
- 2015-10-15 BR BR112017007669A patent/BR112017007669A2/pt not_active Application Discontinuation
- 2015-10-15 ES ES15850568T patent/ES2949827T3/es active Active
- 2015-10-15 HU HUE15850568A patent/HUE062326T2/hu unknown
- 2015-10-15 KR KR1020177013085A patent/KR102134873B1/ko active IP Right Grant
- 2015-10-15 CA CA2964475A patent/CA2964475C/en active Active
- 2015-10-15 AU AU2015332456A patent/AU2015332456A1/en not_active Abandoned
- 2015-10-15 RS RS20230541A patent/RS64339B1/sr unknown
- 2015-10-15 CN CN201580055836.4A patent/CN107075541B/zh active Active
- 2015-10-15 PL PL15850568.5T patent/PL3207149T3/pl unknown
-
2017
- 2017-04-12 IL IL251703A patent/IL251703B/en active IP Right Grant
- 2017-04-12 SA SA517381298A patent/SA517381298B1/ar unknown
- 2017-04-21 MX MX2022003939A patent/MX2022003939A/es unknown
-
2019
- 2019-12-09 AU AU2019279929A patent/AU2019279929B2/en active Active
-
2020
- 2020-06-11 JP JP2020101632A patent/JP6928695B2/ja active Active
-
2021
- 2021-12-16 US US17/552,748 patent/US20220160817A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SA517381298B1 (ar) | تركيبة صيدلية بثبات محسن | |
MX2017004592A (es) | Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos. | |
MX346167B (es) | Procedimientos para la preparacion de composiciones inyectables de liberacion controlada. | |
MX2023006541A (es) | Formulaciones de dosis fija. | |
MX356111B (es) | Composiciones farmaceuticas disuasorias de abuso, de liberacion inmediata. | |
WO2013036309A3 (en) | Sustained release formulations for delivery of proteins to the eye and methods of preparing same | |
PH12014502668A1 (en) | Paliperidone implant formulation | |
RS54024B1 (en) | GASTRORETENCY FORMULATION OF MEDICINES AND SYSTEMS FOR DELIVERY AND METHODS OF THEIR PREPARATION USING FUNCTIONALIZED CALCIUM CARBONATE | |
EA033537B1 (ru) | Инъекционная композиция с контролируемым высвобождением, содержащая жидкий носитель с высокой вязкостью | |
NZ703321A (en) | Risperidone or paliperidone implant formulation | |
SG194175A1 (en) | Polymer conjugated prostaglandin analogues | |
MX2018001499A (es) | Sistema para la entrega de polimeros liquidos para la administracion prolongada de farmacos. | |
HRP20200704T1 (hr) | Vodena formulacija koja sadrži paracetamol i ibuprofen | |
NZ727834A (en) | Fast acting orally disintegrating film | |
MY167777A (en) | A pharmaceutical composition comprising electrohydrodynamically obtained fibres, the composition having improved residence time on the application site | |
MX2019005775A (es) | Formulacion farmaceutica parenteral que contiene acido carglumico. | |
WO2012010938A3 (en) | Pharmaceutical composition of cefditoren pivoxil | |
WO2016027160A3 (en) | Nasal composition comprising mixture of hyaluronic acids and saline solution | |
WO2016055111A8 (en) | Amphiphilic copolymers their preparation and use for the delivery of drugs | |
WO2016008401A8 (zh) | 一种含多西他赛的药物组合物 | |
MX2017016978A (es) | Composicion farmaceutica de heparinas de bajo peso molecular. | |
MY180957A (en) | Chloroprocaine-based pharmaceutical composition for repeated intrathecal administration | |
UA111566C2 (uk) | Фармацевтична композиція пролонгованого вивільнення морфолінію [(5-метил-1н-1,2,4-триазол-3-іл)тіо]ацетату | |
GR1008804B (el) | Συνθεσεις για ιατρικη χρηση οι οποιες περιλαμβανουν υαλουρονικο οξυ ή αλατα αυτου, αμινοξεα, βιταμινες, ανοργανα αλατα και αλλα συστατικα | |
MX2014003939A (es) | Sistema farmaceutico para la administracion oral de sustancias terapeuticas sensibles. |